Invention Grant
- Patent Title: Immunocytes expressing a chimeric antigen receptor binding to cancer cells and TNF-related apoptosis-inducing ligand (trail)
-
Application No.: US16771918Application Date: 2020-03-10
-
Publication No.: US11649282B2Publication Date: 2023-05-16
- Inventor: Mihue Jang , Eunsung Jun , Anna Ju
- Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY , THE ASAN FOUNDATION , UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
- Applicant Address: KR Seoul
- Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY,THE ASAN FOUNDATION,UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
- Current Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY,THE ASAN FOUNDATION,UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
- Current Assignee Address: KR Seoul; KR Seoul; KR Ulsan
- Agency: Birch, Stewart, Kolasch & Birch, LLP
- Priority: KR 20190029845 2019.03.15 KR 20190120852 2019.09.30
- International Application: PCT/KR2020/003321 2020.03.10
- International Announcement: WO2020/189942A 2020.09.24
- Date entered country: 2020-06-11
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K35/17 ; C07K14/705 ; C12N15/86 ; A61P35/00 ; C07K14/725 ; C12N5/0783 ; A61K38/00 ; A61K39/00
Abstract:
Provided are a genetically modified immunocyte expressing a chimeric antigen receptor (CAR) comprising an antigen binding domain specifically binding to cancer cells and/or expressing TRAIL, a composition for preventing or treating cancer, the composition comprising the immunocytes, a cell therapeutic agent, a method of providing information for cancer diagnosis, and a method of preparing the genetically modified immunocyte.
Public/Granted literature
- US20210371515A1 IMMUNOCYTES WITH IMPROVED CANCER-FIGHTING ABILITY Public/Granted day:2021-12-02
Information query
